What are the best treatments for Fibrous Dysplasia?

Treatment for Fibrous Dysplasia is highly individualized, focusing on pain management, preventing skeletal fractures, and correcting deformities through a combination of bisphosphonate therapy and orthopedic surgery. Because Fibrous Dysplasia affects each patient differently—ranging from a single bone lesion to extensive multi-skeletal involvement—care must be coordinated by a multidisciplinary team to address the specific needs of the skeletal site and the patient’s overall bone health.

What are the primary medical and surgical treatments for Fibrous Dysplasia?

There is currently no cure for Fibrous Dysplasia, so clinical management focuses on symptom control and structural support. For patients experiencing significant bone pain or those with high turnover lesions, clinicians often prescribe bisphosphonates. These medications, such as pamidronate (Aredia) or zoledronic acid (Reclast/Zometa), may help reduce pain and improve bone density, though their ability to alter the underlying disease process remains a subject of ongoing research. Surgical intervention is often necessary to address structural failure, such as pathologic fractures or severe bone deformity. Common surgical procedures include curettage (scraping out the fibrous tissue) combined with bone grafting, or internal fixation (using rods or plates) to stabilize affected limbs.

What does a multidisciplinary care team look like for Fibrous Dysplasia?

Because Fibrous Dysplasia can affect various body systems—especially when associated with syndromes like McCune-Albright—a team-based approach is essential. A comprehensive care team typically includes:

• Endocrinologist: To monitor for hormone-related complications, especially if the patient has polyostotic Fibrous Dysplasia.


• Orthopedic Surgeon: To manage fractures, correct deformities, and perform stabilization surgeries.


• Physical and Occupational Therapists: To maintain range of motion, build surrounding muscle strength, and provide assistive devices.


• Pain Management Specialist: To develop strategies for chronic pain, which is a frequent challenge for our 280 community members on DiseaseMaps.org.


• Geneticist: To provide counseling regarding the GNAS gene mutation associated with the condition.

What are the emerging treatments and research directions?

Medical researchers are currently investigating targeted therapies that address the underlying GNAS mutation causing Fibrous Dysplasia. Clinical trials are exploring the use of denosumab (Prolia), a RANK ligand inhibitor, in patients who have not responded to traditional bisphosphonate therapy. While initial data on denosumab shows promise in reducing lesion activity, it must be used with extreme caution under specialized supervision, as there is a risk of rebound hypercalcemia upon discontinuation. Patients are encouraged to monitor clinicaltrials.gov for studies focusing on bone-targeted therapies specific to Fibrous Dysplasia.

How does treatment effectiveness vary between patients?

The clinical course of Fibrous Dysplasia is highly variable. Some individuals may have a single, asymptomatic lesion (monostotic) that requires only periodic monitoring via X-rays or MRI. Others may experience aggressive, polyostotic disease that leads to significant functional impairment. Treatment effectiveness depends on the age of onset, the specific bones involved, and whether the disease is quiescent or active. Because the disease is rare, finding a specialist who has experience with the nuance of lesion progression is vital for achieving the best possible quality of life.

Next steps

• Consult with an orthopedic oncologist or a metabolic bone disease specialist to establish a baseline treatment plan.


• Join the Fibrous Dysplasia community on DiseaseMaps.org to connect with others sharing their experiences and management strategies.


• Maintain a detailed symptom log to discuss during your next consultation, noting any changes in pain levels or mobility.


• Request a referral to a genetic counselor if you have questions about the inheritance or the GNAS mutation.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice; always consult your personal healthcare team for diagnosis and treatment decisions specific to your condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Fibrous Dysplasia.


• Orphanet: Fibrous Dysplasia of bone (ORPHA:333).


• Fibrous Dysplasia Foundation: Clinical guidelines and patient support resources.


• OMIM (Online Mendelian Inheritance in Man): Entry #174800 (Fibrous Dysplasia of bone).